Le Lézard
Classified in: Health, Science and technology
Subject: PER

Former FDA Reviewer and Investigator, Division of Manufacturing and Product Quality, CBER, Joins NDA Partners as Expert Consultant


ROCHELLE, Va., Dec. 3, 2020 /PRNewswire-PRWeb/ -- NDA Partners President Earle Martin announced today that John Godshalk, MSE, MBA, a former Reviewer and Investigator in the FDA Division of Manufacturing and Product Quality in CBER, has joined the firm as an Expert Consultant. As an FDA Reviewer, he was responsible for reviewing CMC sections of BLA submissions, leading pre-approval inspections for new biologics, device, and biotechnology products, conducting meetings with industry, and developing regulatory strategies. He is an expert in CMC, quality, and facility issues for cell and gene therapies and has experience with biologics, vaccines, drugs, drug/device combinations, biologic devices, and in vitro diagnostics.

In addition to his FDA experience, Mr. Godshalk has also consulted with small to large biopharma companies on CMC, quality strategy, quality assurance, product development and manufacturing, GMP systems for the US and EU, and auditing and training. Early in his career, he was a Research Engineer at Westvaco Corp. and Pilot Plant Manager at Energy BioSystems Corp.

According to Dr. Ellen Feigal, Manager of NDA Partners' biologics practice, "We are pleased to welcome Mr. Godshalk to NDA Partners as an Expert Consultant. His FDA and industry experience and expertise in CMC, quality, product development, manufacturing, and cGMP, make him a valuable resource to our clients developing biologics, including cell and gene therapies, vaccines, and biologic devices."

Mr. Godshalk earned his master's degree in chemical and biochemical engineering from Johns Hopkins University and MBA in marketing and finance from the University of Maryland, College Park and the Merrick School, University of Baltimore. He received his bachelor's degree in chemical engineering from North Carolina State University.

About NDA Partners
NDA Partners, a part of The Planet Group, is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact
Earle Martin, President
Office: 540-738-2550
[email protected]

Media Contact

Earle Martin, NDA Partners, 540-738-2550, [email protected]

LinkedIn

 

SOURCE NDA Partners


These press releases may also interest you

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...



News published on and distributed by: